Pathstone Holdings
NTLA icon

Pathstone Holdings’s Intellia Therapeutics NTLA Stock Holding History

Pathstone Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Buy
38,782
+14,942
+63% +$209K ﹤0.01% 1731
2026
Q1 		$306K Sell
23,840
-2,292
-9% -$29.2K ﹤0.01% 1966
2025
Q4 		$235K Sell
26,132
-4,730
-15% -$65.1K ﹤0.01% 2054
2025
Q3 		$533K Buy
30,862
+4,619
+18% +$56.9K ﹤0.01% 1737
2025
Q2 		$246K Buy
26,243
+1,089
+4% +$8.94K ﹤0.01% 1994
2025
Q1 		$179K Buy
25,154
+14,515
+136% +$147K ﹤0.01% 2097
2024
Q4 		$124K Sell
10,639
-2,905
-21% -$45.3K ﹤0.01% 2220
2024
Q3 		$278K Sell
13,544
-6
-0% -$138 ﹤0.01% 2014
2024
Q2 		$303K Buy
13,550
+747
+6% +$17.8K ﹤0.01% 1931
2024
Q1 		$352K Buy
12,803
+5,434
+74% +$151K ﹤0.01% 1843
2023
Q4 		$225K Buy
+7,369
New +$212K ﹤0.01% 2007

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Pathstone Holdings's NTLA Position: Q2 2026 in Review

Pathstone Holdings increased its Intellia Therapeutics (NTLA) stake by 63% in Q2 2026, buying an estimated $209K and bringing the position to 38,782 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

Pathstone Holdings first reported a position in NTLA in Q4 2023 and has held it in 11 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Pathstone Holdings held 38,782 shares of Intellia Therapeutics worth $655K as of Q2 2026.
  • Pathstone Holdings bought 14,942 Intellia Therapeutics shares in Q2 2026, an estimated $209K.
  • Intellia Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1731 holding.
  • Pathstone Holdings first reported a position in Intellia Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.